[Congressional Bills 118th Congress]
[From the U.S. Government Publishing Office]
[H.R. 4053 Introduced in House (IH)]

<DOC>






118th CONGRESS
  1st Session
                                H. R. 4053

   To provide for the review of the scheduling under the Controlled 
Substances Act of buprenorphine-naloxone combination products, and for 
                            other purposes.


_______________________________________________________________________


                    IN THE HOUSE OF REPRESENTATIVES

                             June 13, 2023

   Ms. Kuster (for herself and Mr. Carter of Georgia) introduced the 
   following bill; which was referred to the Committee on Energy and 
  Commerce, and in addition to the Committee on the Judiciary, for a 
 period to be subsequently determined by the Speaker, in each case for 
consideration of such provisions as fall within the jurisdiction of the 
                          committee concerned

_______________________________________________________________________

                                 A BILL


 
   To provide for the review of the scheduling under the Controlled 
Substances Act of buprenorphine-naloxone combination products, and for 
                            other purposes.

    Be it enacted by the Senate and House of Representatives of the 
United States of America in Congress assembled,

SECTION 1. SHORT TITLE.

    This Act may be cited as the ``Studying Suboxone Act''.

SEC. 2. REVIEWING THE SCHEDULING OF BUPRENORPHINE-NALOXONE COMBINATION 
              PRODUCTS.

    (a) Secretary of HHS.--The Secretary of Health and Human Services 
shall--
            (1) review and, as appropriate, update the scientific and 
        medical evaluation conducted under section 201(b) of the 
        Controlled Substance Act (21 U.S.C. 811(b)) with respect to 
        buprenorphine-naloxone combination products; and
            (2) update, as necessary, the Secretary's scheduling 
        recommendation under such section with respect to such 
        products.
    (b) Attorney General.--The Attorney General shall--
            (1) review the recommendations provided by the Secretary 
        under subsection (a), and all other relevant data with respect 
        to the scheduling of buprenorphine-naloxone combination 
        products;
            (2) consider the factors listed in subsection (c) of 
        section 201 of the Controlled Substance Act (21 U.S.C. 811) 
        with respect to such products; and
            (3) consistent with such section 201, make such scheduling 
        changes with respect to such products as the Secretary may 
        determine appropriate.
                                 <all>